BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
August 11, 2016 7:15 AM EDT
TEL AVIV, Israel, Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:Â BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30, 2016.
Highlights and achievements during second quarter of 2016 and to date:
Submission of regulatory filings to initiate Phase 2a study in pancreatic cancer for BL-8040 in combination with Merck's KEYTRUDA®, under immuno-oncology collaboration with Merck announced earlier this year
Signing of additional immuno-oncology collaboration, this time...
More
August 11, 2016 6:45 AM EDT
TEL AVIV, Israel, August 11, 2016 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who joined the Company in 2004, and has served as its Chief Executive Officer since 2010. Â Dr. Savitsky will serve as... More
